Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer

BACKGROUND: This study aimed to investigate whether an immunohistochemical prognostic model (IHC4 score) can predict the prognosis and the chemotherapy benefit in patients with estrogen receptor‐positive (ER+)/human epidermal growth receptor 2–negative (HER2−) metastatic breast cancer (MBC). MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Liang, Chen, Kai, Tan, Cui, Li, Jianbin, Luo, Jiayue, Yang, Yaping, Li, Yudong, Li, Shunying, Zhu, Liling, Hu, Yue, Liu, Fengtao, You, Qiuting, Peng, Min, Jiang, Zefei, Liu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418366/
https://www.ncbi.nlm.nih.gov/pubmed/32476192
http://dx.doi.org/10.1634/theoncologist.2019-1006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418366/
https://www.ncbi.nlm.nih.gov/pubmed/32476192
http://dx.doi.org/10.1634/theoncologist.2019-1006

Ejemplares similares